Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor

被引:4
|
作者
Piserchio, Andrea [1 ]
Isiorho, Eta A. [2 ]
Dalby, Kevin N. [3 ,4 ]
Ghose, Ranajeet [1 ,5 ,6 ,7 ]
机构
[1] CUNY City Coll, Dept Chem & Biochem, New York, NY 10031 USA
[2] CUNY ASRC, Macromol Crystallizat Facil, New York, NY USA
[3] Univ Texas Austin, Div Chem Biol & Med Chem, Austin, TX 78712 USA
[4] Univ Texas Austin, Interdisciplinary Life Sci Grad Program, Austin, TX 78712 USA
[5] CUNY, Grad Ctr, PhD Program Biochem, New York, NY 10016 USA
[6] CUNY, Grad Ctr, PhD Program Chem, New York, NY 10016 USA
[7] CUNY, Grad Ctr, PhD Program Phys, New York, NY 10016 USA
基金
美国能源部;
关键词
MR 100,000 SUBSTRATE; FACTOR-II; EEF2; KINASE; PHOSPHORYLATION; IDENTIFICATION; MECHANISM; TARGET; EEF-2K; EF-2;
D O I
10.1016/j.jbc.2023.104813
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The calmodulin-activated alpha-kinase, eukaryotic elongation factor 2 kinase (eEF-2K), serves as a master regulator of translational elongation by specifically phosphorylating and reducing the ribosome affinity of the guanosine triphosphatase, eukaryotic elongation factor 2 (eEF-2). Given its critical role in a fundamental cellular process, dysregulation of eEF-2K has been implicated in several human diseases, including those of the cardiovascular system, chronic neuropathies, and many cancers, making it a critical pharmacological target. In the absence of high-resolution structural information, high- throughput screening efforts have yielded small-molecule candidates that show promise as eEF-2K antagonists. Principal among these is the ATP-competitive pyrido-pyrimidinedione inhibitor, A-484954, which shows high specificity toward eEF-2K relative to a panel of "typical" protein kinases. A-484954 has been shown to have some degree of efficacy in animal models of several disease states. It has also been widely deployed as a reagent in eEF-2K-specific biochemical and cell- biological studies. However, given the absence of structural information, the precise mechanism of the A-484954-mediated inhibition of eEF-2K has remained obscure. Leveraging our identification of the calmodulin-activatable catalytic core of eEF-2K, and our recent determination of its long-elusive structure, here we present the structural basis for its specific inhibition by A-484954. This structure, which represents the first for an inhibitor-bound catalytic domain of a member of the alpha-kinase family, enables rationalization of the existing structure-activity relationship data for A-484954 variants and lays the groundwork for further optimization of this scaffold to attain enhanced specificity/potency against eEF-2K.
引用
收藏
页数:6
相关论文
共 21 条
  • [1] The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase
    Lee, Kwangwoon
    Kumar, Eric A.
    Dalby, Kevin N.
    Ghose, Ranajeet
    PROTEIN SCIENCE, 2019, 28 (12) : 2089 - 2098
  • [2] ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin
    Piserchio, Andrea
    Long, Kimberly J.
    Browning, Luke S.
    Bohanon, Amanda L.
    Isiorho, Eta A.
    Dalby, Kevin N.
    Ghose, Ranajeet
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (17)
  • [3] Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by Calmodulin
    Lee, Kwangwoon
    Alphonse, Sebastien
    Piserchio, Andrea
    Tavares, Clint D. J.
    Giles, David H.
    Wellmann, Rebecca M.
    Dalby, Kevin N.
    Ghose, Ranajeet
    STRUCTURE, 2016, 24 (09) : 1441 - 1451
  • [4] Structural basis for the calmodulin-mediated activation of eukaryotic elongation factor 2 kinase
    Piserchio, Andrea
    Isiorho, Eta A.
    Long, Kimberly
    Bohanon, Amanda L.
    Kumar, Eric A.
    Will, Nathan
    Jeruzalmi, David
    Dalby, Kevin N.
    Ghose, Ranajeet
    SCIENCE ADVANCES, 2022, 8 (27)
  • [5] Insights into the regulation of eukaryotic elongation factor 2 kinase and the interplay between its domains
    Pigott, Craig R.
    Mikolajek, Halina
    Moore, Claire E.
    Finn, Stephen J.
    Phippen, Curtis W.
    Werner, Joern M.
    Proud, Christopher G.
    BIOCHEMICAL JOURNAL, 2012, 442 : 105 - 118
  • [6] Mechanisms underlying the relaxation by A484954, a eukaryotic elongation factor 2 kinase inhibitor, in rat isolated mesenteric artery
    Kodama, Tomoko
    Okada, Muneyoshi
    Yamawaki, Hideyuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2018, 137 (01) : 86 - 92
  • [7] Eukaryotic elongation factor 2 kinase inhibitor, A484954 induces diuretic effect via renal vasorelaxation in spontaneously hypertensive rats
    Kodama, Tomoko
    Kameshima, Satoshi
    Otani, Kosuke
    Okada, Muneyoshi
    Yamawaki, Hideyuki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 913
  • [8] Eukaryotic elongation factor 2 kinase inhibitor, A484954 induced diuresis via nitric oxide production in spontaneously hypertensive rats
    Kodama, Tomoko
    Otani, Kosuke
    Okada, Muneyoshi
    Yamawaki, Hideyuki
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2023, 85 (12) : 1314 - 1318
  • [9] Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine
    Adaikkan, Chinnakkaruppan
    Taha, Elham
    Barrera, Iliana
    David, Orit
    Rosenblum, Kobi
    BIOLOGICAL PSYCHIATRY, 2018, 84 (01) : 65 - 75
  • [10] Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition
    Piserchio, Andrea
    Will, Nathan
    Giles, David H.
    Hajredini, Fatlum
    Dalby, Kevin N.
    Ghose, Ranajeet
    JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (15) : 2700 - 2717